Li Hui, Li Qun, Jing Hong, Zhao Jianghai, Zhang Hui, Ma Xuhui, Wei Lunshou, Dai Rujiang, Sun Weihong, Suo Zhimin
Department of Digestion, Huaihe Hospital of Henan University, 475000 Kaifeng, Henan, China.
Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Institute of Hypertension, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.
Front Biosci (Landmark Ed). 2021 Oct 30;26(10):707-716. doi: 10.52586/4981.
: JumonjiC (JmjC) domain-containing protein 5 () plays an important part in cancer metabolism. However, the prognostic value of in most human cancers is unknown yet. We aimed to examine the expression level and prognostic value of , immune cell infiltration in cancer patients, and simultaneously to examine the correlations among them. : The mRNA and protein expression of were analyzed through online Tumor Immune Estimation Resource (TIMER) or immunohistochemistry (IHC) of tissue microarray sections (TMAs) in cancer versus normal tissues. The Kaplan-Meier Plotter databases were used to assess the prognostic values. The connection between the expression of and the abundances of six infiltrating immune cells were explored by TIMER in breast cancer (BRCA), liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC), lung adenocarcinoma (LUAD) and stomach adenocarcinoma (STAD). We used the Cox proportional hazards model to investigate the correlations among clinical outcome, the abundance of immune cell infiltration and expression. : We found that the expression was obviously lower in BRCA, LIHC and lung cancer (LUC) but higher in STAD than in normal tissues. High expression of had a better prognosis only in BRCA, LIHC and LUC but a worse prognosis in STAD. The expression of has a significant connection with the abundance of six kind of infiltrating immune cells. The expression of plus the number of immune-infiltrating B cells or macrophages may jointly serve as a prognostic marker in the above four cancers. : We provided novel evidence of as an essential prognostic biomarker and perspective therapeutic target in BRCA, LUAD, LIHC and STAD.
含JumonjiC（JmjC）结构域蛋白5（）在癌症代谢中起重要作用。然而，在大多数人类癌症中的预后价值尚不清楚。我们旨在研究的表达水平和预后价值、癌症患者中的免疫细胞浸润情况，并同时研究它们之间的相关性。：通过在线肿瘤免疫评估资源（TIMER）或组织微阵列切片（TMA）的免疫组织化学（IHC）分析癌症组织与正常组织中 的mRNA和蛋白表达。使用Kaplan-Meier Plotter数据库评估预后价值。通过TIMER在乳腺癌（BRCA）、肝细胞肝癌（LIHC）、肺鳞状细胞癌（LUSC）、肺腺癌（LUAD）和胃腺癌（STAD）中探索的表达与六种浸润免疫细胞丰度之间的联系。我们使用Cox比例风险模型研究临床结局、免疫细胞浸润丰度和表达之间的相关性。：我们发现，在BRCA、LIHC和肺癌（LUC）中 的表达明显低于正常组织，而在STAD中则高于正常组织。仅在BRCA、LIHC和LUC中，的高表达具有较好的预后，而在STAD中预后较差。的表达与六种浸润免疫细胞的丰度有显著联系。在上述四种癌症中，的表达加上免疫浸润B细胞或巨噬细胞的数量可能共同作为预后标志物。：我们提供了新的证据，证明在BRCA、LUAD、LIHC和STAD中是一种重要的预后生物标志物和潜在的治疗靶点。
